Currentmedical mutual - ohioPolicy N/A

Ruconest

Defines prior authorization, medical necessity, dosing, approval durations, site-of-care management, documentation and waste reporting requirements for Ruconest when billed under the medical or pharmacy benefit for treatment of acute hereditary angioedema (HAE) attacks (types I and II).

Policy Summary

Payermedical mutual - ohio

PolicyRuconest

Policy CodePolicy N/A

Change Typeclarified (administrative dates)

Effective DateMar 19, 2026

Next Review Date

Key ActionPrior approval is required for HCPCS codes J0596, J3490, J3590, or J9999 when Ruconest is billed; submit medical records and documentation supporting diagnosis and lab results.

SourceLink

POLICY UPDATE CHANGES

Policy document shows Initial Effective Date and Last Revised Date of 03/19/2026 but contains no statement of clinical policy change; therefore no material change flagged.

2Covered Indications (HAE types)

1Non-covered Indications (prophylaxis)

1Excluded population (laryngeal attacks)

1Required specialist prescriber

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage stance: covered_with_criteria. Scope: prior authorization, medical necessity, dosing, documentation, site-of-care management, and waste reporting requirements for Ruconest when billed under the medical or pharmacy benefit for treatment of acute hereditary angioedema (HAE) attacks (Types I and II). Indicated use: Ruconest is covered for the treatment of acute HAE attacks (Types I and II) in adults and adolescents. Exclusions: prophylactic use is not approved and effectiveness for laryngeal attacks not established. Laboratory thresholds required for diagnosis/documentation include functional C1-INH protein < 50% of normal, serum C4 level < 14 mg/dL, and C1-INH level (mass) < 19.9 mg/dL. Dosing thresholds include weight cutoff 84 kilograms (50 U/kg if less than 84 kg; 4200 U if ≥84 kg) and maximum of no more than 2 doses per 24 hours with a maximum of 4200 Units per dose.

Key clinical thresholds

Functional C1-INH protein< 50% of normal

Serum C4 level< 14 mg/dL

C1-INH level (mass)< 19.9 mg/dL

Duration - subcutaneous angioedema> 12 hours

Duration - recurrent abdominal pain> 6 hours

Weight threshold for dosing84 kilograms

Maximum dosing per 24 hoursNo more than 2 doses; maximum 4200 Units per dose

Initial Therapy Criteria — HAE Type 1 and 2 Acute Attacks

Prior Authorization

Prior authorization required

Prior authorization is required for Ruconest when billed under HCPCS codes J0596, J3490, J3590, or J9999. Submit medical records and documentation supporting the HAE diagnosis and laboratory results with the PA request; upload via the PA portal or fax per policy.

Affected HCPCS codes: J0596; J3490, J3590, J9999 when determined to be Ruconest
Submit clinical chart notes and laboratory confirmation (see Required diagnostic documentation) with the PA request

Documentation Required

Required diagnostic documentation

Provide laboratory confirmation and clinical history to support the diagnosis: functional C1‑INH measurement, C1‑INH level (mass), and serum C4. Medical records and chart notes demonstrating clinical history must be uploaded through the PA web portal or sent by fax.

Functional C1‑INH protein (documented < 50% of normal) OR
Serum C4 (< 14 mg/dL) AND C1‑INH level (< 19.9 mg/dL)
Upload medical records/chart notes via PA portal or fax

Documentation Required

Specialist prescriber requirement

Initial approval requires Ruconest be prescribed by or in consultation with an allergist, immunologist, hematologist, or a physician who specializes in the treatment of HAE. Document the prescribing clinician or consultation in the submitted records.

Prescriber must be or consult with an allergist, immunologist, hematologist, or HAE specialist
Include documentation of specialist involvement in the PA submission

Documentation Required

Allergy check

Before approval, the provider must confirm the patient does not have a known or suspected allergy to rabbits or rabbit‑derived products and document this determination in the medical record.

Confirm and document no known or suspected rabbit allergy prior to therapy

Billing Rule

Site of care management and restriction

When Ruconest is billed under the medical benefit, administration is restricted to non‑hospital facility‑based locations (e.g., home infusion, provider office, ambulatory infusion center) unless the patient meets site‑of‑care exception criteria. This restriction applies to initial approvals.

Site of care restriction applies to medical‑benefit administrations for initial therapy
Exception criteria may permit other settings if met

Continuation / Renewal Criteria

Documentation Required

Annual specialist assessment for continuation

For continuation/renewal, the patient must have at least one annual assessment by an HAE specialist and documentation of a favorable clinical response to Ruconest (examples: decreased attack duration, rapid onset of symptom relief, complete resolution of symptoms, or decreased attack frequency or severity). Include specialist assessment notes in the PA submission.

At least 1 annual assessment by an HAE specialist required for continuation
Document favorable clinical response (e.g., decreased duration, rapid symptom relief, decreased frequency/severity)

Billing Rule

Site of care management and restriction (reauthorizations)

Site‑of‑care medical necessity criteria and restrictions for medical‑benefit administrations also apply to reauthorizations and continuation of therapy; document site‑of‑care justification or exception criteria when submitting reauthorization requests.

Site‑of‑care rules apply to reauthorizations under the medical benefit
Provide documentation if an exception to the non‑hospital site requirement is requested

Dosing and Administration (Acute HAE Attacks)

Billing Rule

Waste management reporting

Waste management procedures apply when Ruconest is administered by a healthcare professional and billed under J0596. Ruconest is supplied as 2100‑unit vials that contain rabbit protein; unused product and waste must be handled per the policy's waste management requirements.

Applies when administered by a healthcare professional and billed under J0596
Ruconest supplied as 2100 unit vials contains rabbit protein — manage unused drug/waste per policy

Applicable Codes

Prior authorization required HCPCS (specific Ruconest code)HCPCSCovered

J0596

Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units

Prior authorization required - unclassified drug/biologic codes when Ruconest billed under these codesHCPCSCovered

J3490	Unclassified drug - when determined to be Ruconest
J3590	Unclassified biologic - when determined to be Ruconest
J9999	Not otherwise classified antineoplastic/agent - when determined to be Ruconest

Prior Authorization

Prior authorization required

Prior authorization is required for HCPCS codes J0596, J3490, J3590, or J9999 when Ruconest is billed. Submit medical records and documentation supporting diagnosis and required labs with the PA request; this applies to specific and unclassified codes when Ruconest is billed under those codes.

Affected codes: J0596; J3490, J3590, J9999 when determined to be Ruconest
Include supporting documentation and lab results when using unclassified codes

Provider Actions & Requirements

Documentation Required

Required diagnostic documentation

Provide lab confirmations and chart notes: functional C1‑INH, C1‑INH level (mass), and serum C4 as applicable, plus clinical chart notes documenting HAE history. Upload records through the PA portal or fax per policy submission requirements.

Functional C1‑INH (< 50% of normal) OR C4 (< 14 mg/dL) AND C1‑INH level (< 19.9 mg/dL)
Clinical chart notes documenting recurrent angioedema or abdominal pain criteria
Upload via PA web portal or fax

Documentation Required

Specialist prescriber requirement

Initial approvals require the medication be prescribed by or in consultation with an allergist, immunologist, hematologist, or an HAE specialist. Document the prescribing clinician or consultation notes in the PA submission for visibility.

Prescriber must be or consult with an allergist, immunologist, hematologist, or HAE specialist
Include specialist documentation for initial approval

Documentation Required

Allergy check

Prior to administration, the provider must determine and document that the patient does not have a known or suspected allergy to rabbits or rabbit‑derived products. This determination is required before approval and administration.

Confirm and document no known or suspected rabbit allergy before administration

Billing Rule

Site of care management and restriction

Under the medical benefit, administration of Ruconest is restricted to non‑hospital facility‑based locations (home infusion, provider office, ambulatory infusion center) unless site‑of‑care exception criteria are met. This restriction applies to administration and initial approvals; reference the policy definitions for Site of Care management for details.

Administration restricted to non‑hospital facility‑based locations for medical‑benefit claims unless exceptions met
See Site of Care definition in policy definitions for examples (home infusion, provider office, ambulatory infusion center)

Clinical Evidence & Background

Background: Ruconest is a recombinant C1-esterase inhibitor (C1-INH) purified from milk of transgenic rabbits and is indicated for the treatment of acute HAE attacks in adult and adolescent patients. The prescribing information notes that the effectiveness of Ruconest was not established for HAE patients with laryngeal attacks and that safety and efficacy for prophylactic therapy have not been established. Hereditary angioedema is a genetic disorder caused by deficiency or dysfunction of C1-INH, leading to recurrent nonpruritic, nonpitting subcutaneous or submucosal edema (pain, nausea, vomiting, diarrhea) and potentially life-threatening airway swelling; Type I is associated with decreased production and low functional levels, and Type II with dysfunctional inhibitor but normal antigenic level. Evidence sources cited in the policy include the Ruconest prescribing information (Salix Pharmaceuticals, April 2020) and the WAO/EAACI 2021 guideline for management of hereditary angioedema.

Site of care managementRestriction of administration to non-hospital facility-based locations for medical benefit (e.g., home infusion, provider office, ambulatory infusion center) unless exception criteria are met; applies to initial and reauthorizations

Waste ManagementPolicy for reporting/handling unused drug from multi-unit vials; Ruconest supplied as 2100 unit vial containing rabbit protein and waste must be managed per policy

Policy Summary

Payermedical mutual - ohio

PolicyRuconest

Policy CodePolicy N/A

Change Typeclarified (administrative dates)

Effective DateMar 19, 2026

Next Review Date

Key ActionPrior approval is required for HCPCS codes J0596, J3490, J3590, or J9999 when Ruconest is billed; submit medical records and documentation supporting diagnosis and lab results.

SourceLink

On This Page

OpenPayer

Ruconest

Coverage Summary

Initial Therapy Criteria — HAE Type 1 and 2 Acute Attacks

Continuation / Renewal Criteria

Dosing and Administration (Acute HAE Attacks)

Applicable Codes

Provider Actions & Requirements

Clinical Evidence & Background

Unproven / Exclusions

Revision History